Apricus Biosciences, Inc. (APRI)
-NasdaqCM 3.45 
0.10(2.99%) 1:08PM EDT - Nasdaq Real Time Price
| Prev Close: | 3.35 |
|---|
| Open: | 3.40 |
|---|
| Bid: | 3.48 x 1500 |
|---|
| Ask: | 3.49 x 2000 |
|---|
| 1y Target Est: | 5.65 |
|---|
| Beta: | 2.67 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.24 - 3.49 |
|---|
| 52wk Range: | 1.89 - 3.63 |
|---|
| Volume: | 525,018 |
|---|
| Avg Vol (3m): | 189,735 |
|---|
| Market Cap: | 105.37M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.23 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- APRICUS BIOSCIENCES, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material DEDGAR Online(Thu, May 16)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other EventsEDGAR Online(Tue, May 14)
- Apricus Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Apricus Biosciences Provides First Quarter 2013 Corporate UpdateGlobeNewswire(Fri, May 10)
- APRICUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugsat Seeking Alpha(Tue, May 7)
- Apricus Biosciences Announces First Quarter 2013 Financial Results Conference CallGlobeNewswire(Tue, May 7)
- Imminent Catalysts For Small Pharmaceuticalsat Seeking Alpha(Tue, May 7)
- Apricus Biosciences Announces Poster Presentation of Vitaros(R) Data in Men Previously Unresponsive to PDE-5 Inhibitors at American Urological Association Annual MeetingGlobeNewswire(Tue, May 7)
- Global Opportunity for Generic Drug Players: Central and Eastern Europe, Latin America and Parts of Asia are Areas with Fertile Ground for Continued GrowthWall Street Transcript(Thu, May 2)
- Apricus enters into judicial liquidation procedures with units in Franceat theflyonthewall.com(Tue, Apr 30)
- APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial StatementEDGAR Online(Tue, Apr 30)
- Apricus Biosciences to Present at 2013 BIO International ConventionGlobeNewswire(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 11.82 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.55 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Apricus Biosciences, Inc., a pharmaceutical company, develops and commercializes products that are primarily in the field of sexual health. It designs and develops pharmaceutical products based on its NexACT platform.
View More